<p>全球市场受到持续的通货膨胀、不均衡的增长和变化的贸易模式的影响，这种混合局面为那些资产负债表更强的精选低价股创造了机会。虽然许多低价股票在消耗现金并停滞不前，但精英低价股筛选器专注于那些看起来更有能力资助其计划的公司。在持续的价格压力、变化的消费者信号和活跃的中央银行的背景下，本文突出了筛选器中 3 只股票，这些股票在愿意对小型公司进行深入研究的投资者中脱颖而出，成为潜在的高收益投资想法。</p>
<h2>Cronos Group (TSX:CRON)</h2>
<p><strong>概述：</strong> Cronos Group 是一家大麻公司，种植、生产和销售包括干花、预卷烟、电子烟、食品、油和酊剂等大麻产品，旗下品牌包括 Spinach、Lord Jones、Lit 和 Peace Naturals，业务覆盖加拿大、以色列和部分国际市场。</p>
<p><strong>运营：</strong> 该公司通过种植、制造和营销大麻及其衍生产品产生了 1.466 亿加元的收入，主要来自加拿大（9030 万加元），其次是以色列（4180 万加元）和其他国家（1450 万加元）。</p>
<p><strong>市值：</strong> 13.5 亿加元</p>
<p>如果你想要获得大麻的投资机会，同时考虑到潜在的收益和明确的风险，Cronos Group 可能会引起你的注意。该公司拥有 1.466 亿加元的产品收入，在电子烟和食品等高利润类别中具有强大的品牌影响力，并且拥有可观的现金储备且没有债务，这支持了新 Spinach 电子烟和预卷烟等产品的推出。同时，Cronos 仍然报告亏损，并在以色列和德国等关键市场面临监管不确定性，分析师对其价格目标的预期差异很大。对于愿意深入研究的投资者来说，其现金充裕的资产负债表、增长雄心和持续盈利挑战之间的紧张关系是一个关键焦点。</p>
<p>现金充裕、亏损且在严格监管的市场中运营，Cronos 看起来像是一个许多投资者可能只看了一半的难题。通过 Cronos Group 财务健康报告获取完整信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw"/></p>
<p>截至 2026 年 5 月的 TSX:CRON 收入与支出细分</p>
<h2>CEMATRIX (TSX:CEMX)</h2>
<p><strong>概述：</strong> CEMATRIX 在北美制造和安装泡沫混凝土，为基础设施、工业和商业项目（如道路、桥梁、隧道和坡度稳定）提供轻质、可泵送的混凝土。其产品用于承包商希望减轻重量、改善绝缘或填补传统混凝土难以到达的困难空间的地方。</p>
<p><strong>市值：</strong> 8089 万加元</p>
<p>CEMATRIX 在基础设施支出和对低碳材料需求这两个显著主题的交汇处运营。2025 年收入为 4509 万加元，净收入为 406 万加元，分析师预计每年盈利增长超过 20%，这表明一些投资者将该业务视为扩展而不仅仅是生存。创纪录的 7640 万加元的订单积压和 2026 年的新合同赢得了正在进行的工作，但结果仍然不稳定，2026 年第一季度显示净亏损 116 万加元，且该业务集中在北美，外部借款较高。此外，规模可观的回购计划引入了许多投资者可能尚未充分考虑的另一个因素。</p>
<p>订单加速和 7640 万加元的订单积压表明 CEMATRIX 可能不仅仅是一个小众承包商，但 2026 年第一季度的亏损和高借款引发了重大问题，CEMATRIX 的分析报告仅开始回答这些问题。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd3a326e-3c48-4cd3-ae22-6e576f517240/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd3a326e-3c48-4cd3-ae22-6e576f517240/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw"/></p>
<p>截至 2026 年 5 月的 TSX:CEMX 收入与支出细分</p>
<h2>Cannara Biotech (TSX:LOVE)</h2>
<p><strong>概述：</strong> Cannara Biotech 是一家垂直整合的加拿大大麻公司，种植、加工和销售品牌大麻和 CBD 产品，旗下品牌包括 TRIBAL、nugz 和 ORCHID CBD，同时还通过房地产运营产生收入。</p>
<p><strong>运营：</strong> Cannara Biotech 的收入约为 1.088 亿加元来自大麻业务，390 万加元来自房地产，所有报告的收入大约为 1.13 亿加元，均来自加拿大。</p>
<p><strong>市值：</strong> 1.748 亿加元</p>
<p>Cannara Biotech 位于高端大麻品牌和规模化室内生产的交汇处，拥有垂直整合的设施，连续 20 个季度保持正的调整后 EBITDA，并在全国零售市场上不断扩大，包括在魁北克的强大市场份额。同时，最近几个季度显示出利润压力、对单一国家的依赖、较高的外部借款和内部人士抛售。分析师目前预计可观的盈利增长和高于当前的价格目标。对于希望投资于运营执行、出口雄心和估值预期都很重要的大麻股票的投资者来说，这家公司可能值得更仔细地研究其数字、增长叙事和计划中的风险。</p>
<p>加速的品牌推广、20 个季度的正调整后 EBITDA 和出口雄心可能意味着 Cannara Biotech 的故事仅仅讲了一半，分析师对 Cannara Biotech 的预测可能揭示出投资者所忽视的转折点。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d6b315ed-ef67-43ed-b623-7019e7826bc8/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d6b315ed-ef67-43ed-b623-7019e7826bc8/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTEw"/></p>
<p>截至 2026 年 5 月的 TSX:LOVE 盈利与收入历史</p>
<p>本文中的三只股票只是一个起点，完整的精英便士股票筛选器还揭示了另外 11 家公司，它们的现金储备、融资周期和商业模式同样构成了引人注目的故事。使用 Simply Wall St 来识别、分析和筛选对您重要的确切催化剂和叙述，以便您可以专注于由更强的资产负债表支持的便士股票想法。</p>
<h2>掌控您的投资旅程</h2>
<p>如果 CEMATRIX 或这些公司中的任何一家公司引起了您的注意，请在 Simply Wall St 上免费注册，并将您的公司添加到关注列表中，以监控股价与公允价值的对比，并跟踪任何新进展。一旦您采取行动，使用我们的投资组合指挥中心管理您的持股，该中心过滤掉噪音，仅提供最关键、可操作的更新。在您的旅程中，我们的社区允许您从成千上万的投资者观点中筛选出最佳想法。通过及早发现隐藏的催化剂和风险，您将加快决策过程，并始终领先于市场。</p>
<h2>寻找在飞涨前的新选择？</h2>
<p>一些最有趣的想法往往在突破或剧烈动量转变之前暂时处于雷达下。提前扫描这些新股票，考虑您的选择。</p>
<ul>
<li>通过运行 7 只高质量被低估股票，发现现金流强劲和资产负债表稳健的公司，同时在关注追逐下一个故事之前把握机会。</li>
<li>通过扫描 11 只低风险分数的抗压股票，跟踪在其他公司跌倒时仍能保持稳定的企业，看看哪些股票在情绪下滑时仍然看起来强劲。</li>
<li>通过使用精心挑选的 32 只机器人和自动化股票，审查下一代自动化的早期领导者，并筛选出可能与现实世界采用的长期动量相一致的股票。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> AI 股票筛选器和警报</h3>
<p>我们的新 AI 股票筛选器每天扫描市场，以发现机会。</p>
<p>• 分红强劲的公司（收益率 3% 以上）</p>
<p>• 内部人士购买的被低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或者从 50 多个指标中构建您自己的筛选器。</p>
<p>立即免费探索</p>

CRON

CBIH

<p>文章强调了三只具有强大资产负债表的优质低价股：Cronos Group（TSX:CRON）、CEMATRIX（TSX:CEMX）和 Cannara Biotech（TSX:LOVE）。Cronos Group 是一家大麻公司，市值为 13.5 亿加元，年收入为 1.466 亿加元，但面临盈利挑战。CEMATRIX 市值为 8089 万加元，专注于细胞混凝土，拥有 7640 万加元的订单积压，尽管在 2026 年第一季度报告了净亏损。Cannara Biotech 的估值为 1.748 亿加元，年收入为 1.13 亿加元，但面临利润压力和高额借款。投资者被鼓励进一步分析这些公司以寻找潜在的上行空间</p>

<p>Global markets are being pulled in different directions by sticky inflation, uneven growth, and shifting trade patterns, and that mix is creating room for carefully chosen penny stocks with stronger balance sheets. While many low-priced stocks burn through cash and stall out, the Elite Penny Stocks screener focuses on companies that appear better equipped to fund their plans. Against a backdrop of persistent price pressures, changing consumer signals, and active central banks, this article highlights 3 stocks from the screener that stand out as potential high-upside ideas for investors willing to do the work on smaller companies.</p>
<div class="lb-trans"><p>全球市场受到持续的通货膨胀、不均衡的增长和变化的贸易模式的影响，这种混合局面为那些资产负债表更强的精选低价股创造了机会。虽然许多低价股票在消耗现金并停滞不前，但精英低价股筛选器专注于那些看起来更有能力资助其计划的公司。在持续的价格压力、变化的消费者信号和活跃的中央银行的背景下，本文突出了筛选器中 3 只股票，这些股票在愿意对小型公司进行深入研究的投资者中脱颖而出，成为潜在的高收益投资想法。</p>
</div><h2>Cronos Group (TSX:CRON)</h2>
<div class="lb-trans"><h2>Cronos Group (TSX:CRON)</h2>
</div><p><strong>Overview:</strong> Cronos Group is a cannabinoid company that cultivates, produces, and sells cannabis products, including dried flower, pre-rolls, vapes, edibles, oils, and tinctures, under brands such as Spinach, Lord Jones, Lit, and Peace Naturals across Canada, Israel, and select international markets.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cronos Group 是一家大麻公司，种植、生产和销售包括干花、预卷烟、电子烟、食品、油和酊剂等大麻产品，旗下品牌包括 Spinach、Lord Jones、Lit 和 Peace Naturals，业务覆盖加拿大、以色列和部分国际市场。</p>
</div><p><strong>Operations:</strong> The company generates CA$146.6 million from cultivation, manufacturing, and marketing of cannabis and cannabis-derived products, with revenue primarily from Canada (CA$90.3 million), followed by Israel (CA$41.8 million) and other countries (CA$14.5 million).</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过种植、制造和营销大麻及其衍生产品产生了 1.466 亿加元的收入，主要来自加拿大（9030 万加元），其次是以色列（4180 万加元）和其他国家（1450 万加元）。</p>
</div><p><strong>Market Cap:</strong> CA$1.35b</p>
<div class="lb-trans"><p><strong>市值：</strong> 13.5 亿加元</p>
</div><p>Cronos Group may catch your eye if you want cannabis exposure with both upside potential and clear risks to weigh. The company has CA$146.6 million in product revenue, strong brand traction in higher margin categories such as vapes and edibles, and a sizeable cash position with no debt, which supports product launches such as new Spinach vapes and pre-rolls. At the same time, Cronos still reports losses and faces regulatory uncertainty in key markets such as Israel and Germany, and analysts see a wide range of possible outcomes in their price targets. For investors who are willing to do deeper work, the tension between its cash-rich balance sheet, growth ambitions, and ongoing profitability challenges is a key focus.</p>
<div class="lb-trans"><p>如果你想要获得大麻的投资机会，同时考虑到潜在的收益和明确的风险，Cronos Group 可能会引起你的注意。该公司拥有 1.466 亿加元的产品收入，在电子烟和食品等高利润类别中具有强大的品牌影响力，并且拥有可观的现金储备且没有债务，这支持了新 Spinach 电子烟和预卷烟等产品的推出。同时，Cronos 仍然报告亏损，并在以色列和德国等关键市场面临监管不确定性，分析师对其价格目标的预期差异很大。对于愿意深入研究的投资者来说，其现金充裕的资产负债表、增长雄心和持续盈利挑战之间的紧张关系是一个关键焦点。</p>
</div><p>Cash rich, loss making, and operating in tightly regulated markets, Cronos looks like a puzzle that many investors may only be half reading. Get the full picture with the Cronos Group financial health report</p>
<div class="lb-trans"><p>现金充裕、亏损且在严格监管的市场中运营，Cronos 看起来像是一个许多投资者可能只看了一半的难题。通过 Cronos Group 财务健康报告获取完整信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw" alt="" original-src="https://images.simplywall.st/company/49c2cca9-f26c-48fc-add2-8e319554b2fa/chart/revenue-and-expenses-breakdown?date=2026-05-10"/></p>
<p>TSX:CRON Revenue &amp; Expenses Breakdown as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TSX:CRON 收入与支出细分</p>
</div><h2>CEMATRIX (TSX:CEMX)</h2>
<div class="lb-trans"><h2>CEMATRIX (TSX:CEMX)</h2>
</div><p><strong>Overview:</strong> CEMATRIX manufactures and installs cellular concrete across North America, supplying lightweight, pumpable concrete for infrastructure, industrial, and commercial projects such as roads, bridges, tunnels, and slope stabilization. Its products are used where contractors want to reduce weight, improve insulation, or fill difficult spaces that conventional concrete struggles to reach.</p>
<div class="lb-trans"><p><strong>概述：</strong> CEMATRIX 在北美制造和安装泡沫混凝土，为基础设施、工业和商业项目（如道路、桥梁、隧道和坡度稳定）提供轻质、可泵送的混凝土。其产品用于承包商希望减轻重量、改善绝缘或填补传统混凝土难以到达的困难空间的地方。</p>
</div><p><strong>Market Cap:</strong> CA$80.89 million</p>
<div class="lb-trans"><p><strong>市值：</strong> 8089 万加元</p>
</div><p>CEMATRIX operates at the intersection of two notable themes for construction investors: infrastructure spending and demand for lower carbon materials. Revenue of CA$45.09 million and net income of CA$4.06 million in 2025, together with analysts expecting earnings growth above 20% a year, indicate that some investors view the business as scaling rather than just surviving. The record CA$76.4 million backlog and fresh contract wins in 2026 highlight work in hand, yet results remain lumpy, Q1 2026 showed a net loss of CA$1.16 million, and the business is concentrated in North America with high external borrowing. In addition, a sizeable buyback program introduces another factor that many investors may not have fully weighed yet.</p>
<div class="lb-trans"><p>CEMATRIX 在基础设施支出和对低碳材料需求这两个显著主题的交汇处运营。2025 年收入为 4509 万加元，净收入为 406 万加元，分析师预计每年盈利增长超过 20%，这表明一些投资者将该业务视为扩展而不仅仅是生存。创纪录的 7640 万加元的订单积压和 2026 年的新合同赢得了正在进行的工作，但结果仍然不稳定，2026 年第一季度显示净亏损 116 万加元，且该业务集中在北美，外部借款较高。此外，规模可观的回购计划引入了许多投资者可能尚未充分考虑的另一个因素。</p>
</div><p>Accelerating orders and a CA$76.4 million backlog suggest CEMATRIX might be more than a niche contractor, yet the Q1 2026 loss and high borrowing raise big questions that the analysis report for CEMATRIX only starts to answer.</p>
<div class="lb-trans"><p>订单加速和 7640 万加元的订单积压表明 CEMATRIX 可能不仅仅是一个小众承包商，但 2026 年第一季度的亏损和高借款引发了重大问题，CEMATRIX 的分析报告仅开始回答这些问题。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd3a326e-3c48-4cd3-ae22-6e576f517240/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEw" alt="" original-src="https://images.simplywall.st/company/bd3a326e-3c48-4cd3-ae22-6e576f517240/chart/revenue-and-expenses-breakdown?date=2026-05-10"/></p>
<p>TSX:CEMX Revenue &amp; Expenses Breakdown as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TSX:CEMX 收入与支出细分</p>
</div><h2>Cannara Biotech (TSX:LOVE)</h2>
<div class="lb-trans"><h2>Cannara Biotech (TSX:LOVE)</h2>
</div><p><strong>Overview:</strong> Cannara Biotech is a vertically integrated Canadian cannabis company that grows, processes, and sells branded cannabis and CBD products under TRIBAL, nugz, and ORCHID CBD, while also generating income from real estate operations.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cannara Biotech 是一家垂直整合的加拿大大麻公司，种植、加工和销售品牌大麻和 CBD 产品，旗下品牌包括 TRIBAL、nugz 和 ORCHID CBD，同时还通过房地产运营产生收入。</p>
</div><p><strong>Operations:</strong> Cannara Biotech generates about CA$108.8 million from cannabis operations and CA$3.9 million from real estate, with all reported revenue of roughly CA$113.0 million coming from Canada.</p>
<div class="lb-trans"><p><strong>运营：</strong> Cannara Biotech 的收入约为 1.088 亿加元来自大麻业务，390 万加元来自房地产，所有报告的收入大约为 1.13 亿加元，均来自加拿大。</p>
</div><p><strong>Market Cap:</strong> CA$174.8 million</p>
<div class="lb-trans"><p><strong>市值：</strong> 1.748 亿加元</p>
</div><p>Cannara Biotech sits at the intersection of premium cannabis branding and scaled indoor production, with vertically integrated facilities, consistent positive adjusted EBITDA over 20 quarters, and a growing national retail presence, including strong share in Quebec. At the same time, recent quarters show margin pressure, reliance on a single country, higher external borrowing and insider selling. Analysts are currently modeling sizeable earnings growth and a higher price target than today. For investors who want a cannabis stock where operating execution, export ambitions, and valuation expectations all matter, this is a company that may warrant closer reading of the numbers, the growth narrative, and the risks in the plan.</p>
<div class="lb-trans"><p>Cannara Biotech 位于高端大麻品牌和规模化室内生产的交汇处，拥有垂直整合的设施，连续 20 个季度保持正的调整后 EBITDA，并在全国零售市场上不断扩大，包括在魁北克的强大市场份额。同时，最近几个季度显示出利润压力、对单一国家的依赖、较高的外部借款和内部人士抛售。分析师目前预计可观的盈利增长和高于当前的价格目标。对于希望投资于运营执行、出口雄心和估值预期都很重要的大麻股票的投资者来说，这家公司可能值得更仔细地研究其数字、增长叙事和计划中的风险。</p>
</div><p>Accelerating branding, 20 quarters of positive adjusted EBITDA and export ambitions could mean Cannara Biotech’s story is only half told, and the analyst forecasts for Cannara Biotech might reveal the twist investors are missing</p>
<div class="lb-trans"><p>加速的品牌推广、20 个季度的正调整后 EBITDA 和出口雄心可能意味着 Cannara Biotech 的故事仅仅讲了一半，分析师对 Cannara Biotech 的预测可能揭示出投资者所忽视的转折点。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d6b315ed-ef67-43ed-b623-7019e7826bc8/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTEw" alt="" original-src="https://images.simplywall.st/company/d6b315ed-ef67-43ed-b623-7019e7826bc8/chart/earnings-and-revenue-history?date=2026-05-10"/></p>
<p>TSX:LOVE Earnings &amp; Revenue History as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TSX:LOVE 盈利与收入历史</p>
</div><p>The three stocks in this article are just a starting point, and the full Elite Penny Stocks screener surfaces 11 more companies where cash reserves, funding runways, and business models line up into equally compelling stories. Use Simply Wall St to identify, analyze, and filter for the exact catalysts and narratives that matter to you so you can focus on penny stock ideas backed by stronger balance sheets.</p>
<div class="lb-trans"><p>本文中的三只股票只是一个起点，完整的精英便士股票筛选器还揭示了另外 11 家公司，它们的现金储备、融资周期和商业模式同样构成了引人注目的故事。使用 Simply Wall St 来识别、分析和筛选对您重要的确切催化剂和叙述，以便您可以专注于由更强的资产负债表支持的便士股票想法。</p>
</div><h2>Take Control of Your Investment Journey</h2>
<div class="lb-trans"><h2>掌控您的投资旅程</h2>
</div><p>If CEMATRIX or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.</p>
<div class="lb-trans"><p>如果 CEMATRIX 或这些公司中的任何一家公司引起了您的注意，请在 Simply Wall St 上免费注册，并将您的公司添加到关注列表中，以监控股价与公允价值的对比，并跟踪任何新进展。一旦您采取行动，使用我们的投资组合指挥中心管理您的持股，该中心过滤掉噪音，仅提供最关键、可操作的更新。在您的旅程中，我们的社区允许您从成千上万的投资者观点中筛选出最佳想法。通过及早发现隐藏的催化剂和风险，您将加快决策过程，并始终领先于市场。</p>
</div><h2>Seeking Fresh Alternatives Before They Fly?</h2>
<div class="lb-trans"><h2>寻找在飞涨前的新选择？</h2>
</div><p>Some of the most interesting ideas often sit under the radar for now, right before a breakout or sharp momentum shift. Scan these fresh sets of stocks before the crowd and consider your options early.</p>
<div class="lb-trans"><p>一些最有趣的想法往往在突破或剧烈动量转变之前暂时处于雷达下。提前扫描这些新股票，考虑您的选择。</p>
</div><ul>
<li>Spot companies with strong cash flows and solid balance sheets by running the 7 high quality undervalued stocks, while it matters and before attention chases the next story.</li>
<li>Track resilient businesses that may hold up when others stumble by scanning the 11 resilient stocks with low risk scores and see which stocks still look robust if sentiment drops.</li>
<li>Review early leaders in next generation automation by using the curated 32 robotics and automation stocks and filter for stocks that might align with long-term momentum from real-world adoption.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过运行 7 只高质量被低估股票，发现现金流强劲和资产负债表稳健的公司，同时在关注追逐下一个故事之前把握机会。</li>
<li>通过扫描 11 只低风险分数的抗压股票，跟踪在其他公司跌倒时仍能保持稳定的企业，看看哪些股票在情绪下滑时仍然看起来强劲。</li>
<li>通过使用精心挑选的 32 只机器人和自动化股票，审查下一代自动化的早期领导者，并筛选出可能与现实世界采用的长期动量相一致的股票。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票筛选器和警报</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场，以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的公司（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士购买的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建您自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

三只拥有现金充裕资产负债表且具有上涨潜力的优质便士股